Phathom Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · New Jersey, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
100 Campus Dr Ste 102, Florham Park, New...Phone Number
(877) 742-8466Website
www.phathompharma.comRevenue
$239.7 MillionStock Symbol
PHATIndustry
About Phathom Pharmaceuticals
Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for GI disorders. We have licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, an investigational potassium competitive acid blocker (P-CAB) in late clinical-stage development for the treatment of gastric acid-related disorders. Vonoprazan has the potential to be the first gastric anti-secretory agent from a new class approved in the United States, Europe, or Canada in over 30 years.Explore more
Phathom Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Phathom Pharmaceuticals
Compare insights from companies similar to Phathom Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Phathom Pharmaceuticals Tech Stack
A closer look at the technologies used by Phathom Pharmaceuticals
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Phathom Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for GI disorders. We have licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, an investigational potassium competitive acid blocker (P-CAB) in late clinical-stage development for the t... Read More
